Skip to content

Abstract A027: Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer

Sep 2026 · Cancer Research · 0 citations

TL;DR

It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.

Abstract

Loss of the Y chromosome (LOY) is a common somatic alteration in aging males and many cancer entities, yet its functional role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. We sought to determine whether LOY is a recurrent, functionally consequential event in male PDAC and to define its impact on tumor biology and treatment response. We analyzed whole-genome sequencing data from 239 male PDAC patients across two independent cohorts (Toronto COMPASS and resected PDAC cases), integrating genomic and transcriptomic profiling. CRISPR/Cas9-mediated Y chromosome knockout was performed in male PDAC cell lines (YAPC and HuP-T3) to model LOY. Functional assays included RNA-seq, whole-genome sequencing, FISH, 2D/3D culture, anoikis resistance, subcutaneous and intravenous xenografts, and DNA methylation profiling. Single-cell RNA-seq data from PDAC patients were used to validate LOY-associated programs. A RNA-based LOY probability score (rLOY score) was applied to patient-derived models and clinical cohorts to assess treatment response and survival upon LOY stratification. As previously reported, LOY was identified in ∼50% of male PDAC patients. Here, we demonstrate for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype. LOY remains strongly associated with TP53 mutations while being independent of other large-scale genomic alterations. CRISPR-mediated Y chromosome loss induced a robust epithelial-to-mesenchymal transition (EMT), characterized by mesenchymal morphology, upregulation of mesenchymal markers, enhanced anoikis resistance, and increased lung metastatic seeding in vivo. In contrast, LOY clones exhibited impaired subcutaneous tumor formation, consistent with EMT-associated loss of epithelial tumorigenic capacity. Integrative analyses across bulk tumors, single-cell datasets, and CRISPR-engineered models converged on EMT as the dominant LOY-driven program. Mechanistically, LOY disrupted epigenetic regulation, leading to genome-wide DNA hypomethylation at EMT- and basal-defining loci, reduced chemotherapy sensitivity, and transcriptional reprogramming toward the basal subtype. Analysis of patient-derived organoids and primary cell lines confirmed that LOY is associated with resistance to gemcitabine, irinotecan, and nab-paclitaxel. In clinical cohorts, LOY correlated with progressive disease, reduced treatment response, and overall survicial, particularly in resected PDAC patients. This study establishes LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance. LOY is not a bystander but a functionally consequential alteration with direct clinical relevance. Its high prevalence, ease of detection via FISH on FFPE tissue, and strong association with aggressive disease position LOY as a clinically accessible biomarker with direct therapeutic relevance. Madeleine Dorsch, Felix E.G. Beaudry, Anna K. Baginska, Peihua Zao, Belen Otero-Carrasco, Mei-Ju May. Chen, Kathleen Schlüter, Maria Llamazares-Prada, Hans-Ullrich Schildhaus, Katja Steiger, Roland Schwarz, Jens T. Siveke, Alexander Schramm, Christoph Plass, Florian Rambow, Faiyaz Notta, Barbara T. Grünwald, Barbara M. Grüner. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr A027.

View source

Similar papers

Open access Sep 2026

Recurrent deletions and regulatory disruption of the Y chromosome in cancer

High-coverage whole-genome sequencing, large-scale transcriptomics, and eQTL are used to map male cancer cell lines, revealing a region-specific LOY landscape with recurrent euchromatic deletions affecting protein-coding genes and non-coding elements and motivating validation in primary tumor cohorts.

Trini Nguyen, Aditi Kuchi, Hong-Yu Liu et al. · 0 citations
Sep 2026

Abstract B066: Convergent cell-state programs characterize BRCA2 -reversion-independent resistance in pancreatic cancer

This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.

J. Romero, Yi-Fan Wang, Edward Shanbedi et al. · 0 citations
Open access Aug 2026

Single-Cell RNA-Seq Reveals Chromosomal Instability-Associated Transcriptomic Profiles in Breast Cancer

Single-cell approaches such as scRNA-seq provide a powerful framework to elucidate CIN-related mechanisms and to identify potential biomarkers of BC aggressiveness and prognosis, supporting their further application in the study of intratumoral heterogeneity.

María Paula Meléndez-Flórez, N. Rangel, Milena Rondón-Lagos et al. · 0 citations
Open access Oct 2026

Methylation profiling reveals epigenetic programs associated with chr18 loss in small intestinal neuroendocrine tumors

Small intestinal neuroendocrine tumors (SI-NETs) are characterized by a low mutational burden and limited recurrent driver mutations, suggesting that other mechanisms contribute to tumor development. One of the most frequent genomic alterations in SI-NETs is loss of heterozygosity on chromosome 18 (chr18del), which...

F. Axling, S. Backman, Per Hellman et al. · 0 citations
Sep 2026

Abstract A094: Mapping early Pancreatic Cancer evolution through enhancer reprogramming and transcription factor interactomes

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, with poor survival largely driven by late-stage diagnosis. Approximately 85% of patients present with advanced disease, limiting curative treatment options. A major challenge in PDAC is the absence of biomarkers capable of identify...

Paula D. Santos, Lisa Young, Sarah Baloul et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.